复宏汉霖:HLX22乳腺癌治疗II期临床试验完成首例患者给药

美港电讯
23 Apr

【复宏汉霖:HLX22乳腺癌治疗II期临床试验完成首例患者给药】金十数据4月23日讯,复宏汉霖近日宣布,公司创新型抗HER2单抗HLX22单抗注射液联合德曲妥珠单抗,治疗HER2低表达HR阳性的局部晚期或转移性乳腺癌的II期临床研究(HLX22-BC201)于中国境内完成首例患者给药。继HER2阳性胃癌之后,HLX22的治疗领域再度拓宽至乳腺癌疾病领域。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10